- Source type
- Review
- Access type
- Publisher
- Publisher
- Lasers in Surgery and Medicine
- Date
- 2018
- Added
- 2026-07-07
- Updated
- 2026-07-07
Trust profile
VV Source Trust Matrix v1.0
VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.
88
Peer-reviewed research publisher
- Publisher type
- Peer-reviewed journal
- Bias profile
- Moderate
This source is strongest for clinical outcomes and mechanism and weaker for regulatory status and trial discovery.
VV Source Fit Score 1.0
Fit by use case
Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.
- Regulatory status
- 65/100
- Context Source
- Clinical outcomes
- 92/100
- Primary Anchor
- Mechanism
- 90/100
- Primary Anchor
- Safety
- 86/100
- Strong Support
- Consumer context
- 72/100
- Context Source
- Trial discovery
- 65/100
- Context Source
Best used for
- Primary studies
- Systematic reviews
- Mechanistic research
Weak for
- Regulatory status
- Universal consumer recommendations
Used in Viral Vitalism
Red Light Therapy: Mitochondrial Medicine or Expensive Lamp Culture?
Roles: Supporting evidence
Show section-level references
- Article source list
- Photobiomodulation is plausible, but plausibility is not a protocol
- Skin, pain, and hair are the more grounded consumer lanes
- Testosterone and thyroid claims are where the hype gets dangerous
- Brain performance and fat loss claims need a higher bar
- More light is not automatically better
- The buyer boundary: specs before vibes
- VV verdict
- Does red light really affect mitochondria?
- Is red light good for skin?
- Can red light boost testosterone?
- Can red light regrow hair?
- What should consumers check before buying a red light device?
Related studies
Related sources
Contemporary Pediatrics: FDA approves risankizumab for pediatric plaque psoriasis and psoriatic arthritis
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 91
- Publisher
- Contemporary Pediatrics
- Access
- Publisher
- Usage
- 0 connections
FDA prescribing information: Skyrizi 2026 label
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 94
- Publisher
- FDA prescribing information
- Access
- Official
- Usage
- 0 connections
AbbVie: Skyrizi approved for pediatric psoriatic disease
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 60
- Publisher
- AbbVie
- Access
- Publisher
- Usage
- 0 connections
Low-level laser therapy for the treatment of androgenic alopecia: a review
Hair-loss source for a better-supported consumer lane than testosterone, fat loss, or whole-body longevity claims.
- Trust score
- 88
- Publisher
- Lasers in Medical Science
- Access
- Publisher
- Usage
- 13 connections
Biphasic dose response in low level light therapy
Dose-response source for the core red-light caveat: more light is not automatically better, and dose windows matter.
- Trust score
- 88
- Publisher
- Dose-Response
- Access
- Publisher
- Usage
- 13 connections
Low-level laser therapy for neck pain: systematic review and meta-analysis
Clinical outcomes source for one of the stronger pain-related low-level laser therapy evidence lanes.
- Trust score
- 88
- Publisher
- The Lancet
- Access
- Publisher
- Usage
- 13 connections